Navigation Links
New antiviral drug shows promise for dramatic improvement in hepatitis C treatment
Date:8/9/2010

INDIANAPOLIS Adding a direct acting anti-viral drug to the standard treatment regimen for hepatitis C significantly increases the cure rate in the most difficult to treat patients, according to a research report published Monday in the online edition of the journal The Lancet.

The research team, led by Paul Kwo, M.D., of Indiana University School of Medicine, reported that adding the drug nearly doubled the treatment's effectiveness when given for 48 weeks in one treatment arm of the study.

An estimated 3.2 million Americans and 170 million people worldwide are infected with the hepatitis C virus, but many do not know it. In the United States, 70 percent of affected individuals are infected with genotype 1 hepatitis C, the most difficult to treat. Although there may be no symptoms for years, long-term infection can cause cirrhosis and the disease is a leading cause of liver cancer and liver transplantation. Hepatitis C infections occur mainly through transmission of infected blood, such as via injection drug use, and there is no vaccine.

Currently fewer than half of patients with genotype 1 hepatitis C are treated effectively by the standard combination of two drugs, peginterferon alfa-2b plus ribavirin, which is typically given for 48 weeks. The treatment can be difficult for some patients due to anemia and other side effects.

Adding the drug boceprevir increased the cure rate to as high as 75 percent in those who received 48 weeks of the three-drug combination therapy, compared to 38 percent of those in the control group, who received the standard two-drug treatment for 48 weeks, said Dr. Kwo, associate professor of medicine at the IU School of Medicine. The two-year phase 2 trial was conducted at 67 sites with 520 patients in the U.S., Canada and Europe.

In the boceprevir study, known as the SPRINT-1 trial, researchers tested several different options to evaluate the effectiveness of the combination therapy:

  • To test whether the addition of boceprevir could make it possible to shorten treatment times, some patients were randomly selected to receive the three-drug combination for 28 weeks, some for 48 weeks.
  • Researchers also investigated whether a 4 week lead-in with the standard two-drug combination prior to the addition of boceprevir to the treatment regime could improve sustained virologic response rates. The goal was to see if allowing the interferon and ribavirin to reach steady state levels -- which would activate the immune system and reduce virus levels -- before adding boceprevir would improve the response rates as well as reduce the virus' ability to develop resistance to boceprevir, said Kwo.
  • In another arm of the trial, researchers tested whether a lower dose of ribavirin could reduce the anemia side effects while still treating the virus effectively.

"Both 28- and 48-week boceprevir regimens significantly increased sustained virologic response rates which is the best definition of a cure we have compared to the 48 week control," said Dr. Kwo. "The 48-week treatment arm with 4 weeks of peg interferon lead-in and 44 weeks of peg interferon, ribavirin, and boceprevir led to the largest improvement over the control group ever reported. That's very impressive."

Boceprevir, a product of Merck & Co., is an HCV protease inhibitor a compound designed to block a function key to viral reproduction in the cell. Boceprevir directly targets the hepatitis C virus, Kwo noted, while peginterferon and ribavirin are less specific, acting more generally to stimulate the body's virus-fighting immune system.

The best results were reported for the 103 patients who were treated for four weeks with the standard two drug regiment, followed by 44 weeks of the three-drug regimen including boceprevir: 75 percent of these patients tested negative for evidence of the virus six months after the end of treatment. Results for the other treatment arms were:

  • 67 percent of those who received the three drug regimen for 48 weeks with no lead-in treatment tested negative for the virus (103 patients).
  • 56 percent of those who received the two-drug lead-in for four weeks, followed by 24 weeks of the three drug treatment tested negative for the virus (103 patients).
  • 54 percent of those who received the three-drug treatment for 28 weeks with no lead-in tested negative for the virus (107 patients).
  • 38 percent of the control group, who received the standard two-drug treatment for 48 weeks tested negative for the virus (104 patients).

Patients receiving the low-dose of ribavirin did not fare as well just 36 percent were virus-free after 48 weeks of treatment.

"Based on this phase 2 study, it appears that if this drug receives final approval approximately two-thirds of patients will be able to be treated successfully with 28 weeks of treatment and one-third will need 48 weeks of treatment, though this will require confirmation from the phase 3 trials, from which preliminary results were recently released," said Dr. Kwo.


'/>"/>

Contact: Eric Schoch
eschoch@iupui.edu
317-274-7722
Indiana University School of Medicine
Source:Eurekalert  

Related medicine news :

1. Longer Antiviral Therapy Reduces Lung Transplant Complications
2. Antiviral therapy during compensated cirrhosis most cost-effective approach
3. New Study: Improved Immune System with Gene-Eden, a Natural Antiviral Supplement that Targets Chronic Viruses
4. New anti-viral drug shows promise for dramatic improvement in hepatitis C treatment
5. Surgery better than radiation, hormone treatments for some prostate cancer, study shows
6. Women Can Safely Get Pregnant Right After Miscarriage, Study Shows
7. Study shows splitting bowel preparation dosage is most effective cleansing method before colonoscopy
8. Epilepsy Drugs Dont Raise Suicide Risk, Study Shows
9. Iron-regulating protein is strong predictor of breast cancer prognosis, study shows
10. Brain study shows that thinking about God reduces distress -- but only for believers
11. Survey of coastal residents shows Gulf oil spill has significant impact on families
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New antiviral drug shows promise for dramatic improvement in hepatitis C treatment
(Date:8/22/2017)... (PRWEB) , ... August 22, 2017 , ... ... luxurious collection of unique masks and serums that perfectly fuse the beauty of ... advancements, at the 2017 Indie Beauty Expo on August 23rd & 24th in ...
(Date:8/22/2017)... ... 2017 , ... The old adage “you are what you ... healthy foods. But this well-known piece of nutrition advice ignores that an individual’s ... not only on properties of the food but also on properties of the ...
(Date:8/22/2017)... , ... August 22, 2017 , ... ... pleased to announce the addition of Zack Tisch as the firm’s new Consulting ... KLAS-ranked healthcare IT consulting firm’s national accounts, from assisting clients with initial vendor ...
(Date:8/22/2017)... CA (PRWEB) , ... August 22, 2017 , ... ... cycle management (RCM) solutions, announced recently the availability of a new professional fee ... in appreciation for their service to the healthcare industry. E/M coding is complex ...
(Date:8/22/2017)... DFW Metroplex, TX (PRWEB) , ... August 22, 2017 , ... Five Star Glass is ... They provide repair and replacement of auto glass for most makes and models, in ... area in the USA. , They have been a family owned business for the ...
Breaking Medicine News(10 mins):
(Date:8/4/2017)... , Aug. 3, 2017  Agragen, LLC, ... company active in the biopharmaceutical, nutraceutical, and aquacultural ... development of its lead drug candidates, AGR131.  This ... proinflammatory cytokine from the blood of patients suffering ... and inflammatory bowel disease. ...
(Date:8/2/2017)... -- CaryRx, a next-generation full-service pharmacy, has announced the launch ... the Washington D.C. metropolitan area. CaryRx ... of medications through the convenience of its patient-friendly mobile app. ... one hour to any location in D.C. ... service to Washington D.C. ," says Areo ...
(Date:7/28/2017)... CHICAGO, July 28, 2017 Hill-Rom Holdings, Inc. ... fiscal third quarter ended June 30, 2017, and updated ... For the fiscal third quarter, ... to $0.68 per diluted share in the prior-year period. ... of $0.39 per diluted share primarily related to the ...
Breaking Medicine Technology: